Sempresto

About the offering

Sempresto is a Weston, MA-based medical device startup founded in 2024 that is developing a phone-integrated epinephrine autoinjector designed to address the well-documented 'failure-to-carry' problem among the 33 million Americans living with life-threatening allergies. The core product attaches directly to a MagSafe/Qi2-compatible smartphone, making the life-saving device as easy to carry as a phone. The technology was originally invented by Dr. Edmund Pribitkin, Chief Physician Executive and EVP at Jefferson Health, and is protected by 15 issued patents and 10 pending applications covering device design, integration, safety mechanisms, heat shielding, and connectivity, both domestically and internationally. In December 2025, Thomas Jefferson University announced a broad strategic partnership with Sempresto, expanding on an exclusive license for the core platform technology. The company has raised approximately $2.6M in angel investment led by Dominic J. Frederico, President and CEO of Assured Guaranty, and has developed working prototypes. The product is accompanied by a companion app that provides dosing guidance, refill reminders, and integration with a 24/7 emergency medicine tele-health platform (Health Alliance Global's Dr. Triage), as well as GPS-based EMT routing. Sempresto is pursuing FDA clearance via the 505(b)(2) regulatory pathway, which allows the company to leverage existing epinephrine safety and efficacy data without full clinical trials, with an FDA filing targeted within 18 months and a commercial launch planned for 2028. The company is also targeting EMEA clearance. The addressable market is estimated at $3B+ in the US and $6B+ globally, with the epinephrine autoinjector market as the initial focus and expansion planned into other rescue medications (e.g., seizure treatments, nasal sprays). The revenue model includes device sales through standard pharmaceutical channels (target retail price below the current market average of ~$225/unit), recurring annual prescription refills, and subscription revenue sharing from the tele-health companion app. Projected gross margins exceed 85% at scale, with unit costs expected to drop below $20 at volume. The leadership team includes Co-Founder and CEO Elizabeth Reczek (Harvard BA, MIT PhD, Harvard Medical School postdoc), Co-Founder and Executive Chairman Shawn Marcell (4x exited founder with exits including ReadCoor at $350M), and Co-Founder and SAB Chairman Dr. Edmund Pribitkin (Johns Hopkins BA, Penn Medicine MD, Wharton MBA). Collectively the team has led 3 IPOs, filed 12 SEC Form S-1s, completed 30+ business development transactions, and holds 36 issued US patents. An independent study of 300 allergy patients found 92% would purchase Sempresto instead of or in addition to their current autoinjector. The company has raised $510,440 from 46 investors on Wefunder toward a $750,000 goal, with a minimum investment of $100. Potential exit pathways identified include early acquisition upon FDA filing, post-launch acquisition, or IPO.

FAQ